| 1 |
Tran TA, Kim YH, Duong TH, Thangaraj J, Chu TH, Jung S, Kim IY, Moon KS, Kim YJ, Lee TK, Lee CW, Yun H, Lee JJ, Lee HJ, Lee KH, Jung TY. Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model. Front Immunol 2022;13:1009484. [PMID: 36703992 DOI: 10.3389/fimmu.2022.1009484] [Reference Citation Analysis]
|
| 2 |
Luo X, Wang Q, Tang H, Chen Y, Li X, Chen J, Zhang X, Li Y, Sun J, Han S. A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma. Medicina (Kaunas) 2022;59. [PMID: 36676646 DOI: 10.3390/medicina59010023] [Reference Citation Analysis]
|
| 3 |
Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther 2022;7:258. [PMID: 35906199 DOI: 10.1038/s41392-022-01102-y] [Reference Citation Analysis]
|
| 4 |
Watchmaker PB, Colton M, Pineo-Cavanaugh PL, Okada H. Future development of chimeric antigen receptor T cell therapies for patients suffering from malignant glioma. Curr Opin Oncol 2022. [PMID: 35855503 DOI: 10.1097/CCO.0000000000000877] [Reference Citation Analysis]
|
| 5 |
Rodríguez-camacho A, Flores-vázquez JG, Moscardini-martelli J, Torres-ríos JA, Olmos-guzmán A, Ortiz-arce CS, Cid-sánchez DR, Pérez SR, Macías-gonzález MDS, Hernández-sánchez LC, Heredia-gutiérrez JC, Contreras-palafox GA, Suárez-campos JDJE, Celis-lópez MÁ, Gutiérrez-aceves GA, Moreno-jiménez S. Glioblastoma Treatment: State-of-the-Art and Future Perspectives. IJMS 2022;23:7207. [DOI: 10.3390/ijms23137207] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 6 |
Niedbała M, Malarz K, Sharma G, Kramer-Marek G, Kaspera W. Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations. Onco Targets Ther 2022;15:437-68. [PMID: 35509452 DOI: 10.2147/OTT.S215997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
